Posted inCardiagtech

Differential Diagnosis of Cystitis: A Comprehensive Guide for Clinicians

No Comments

Introduction

Cystitis, commonly known as a bladder infection, is an inflammation of the urinary bladder, most often caused by a bacterial infection. It falls under the broader category of lower urinary tract infections (UTIs). While seemingly straightforward, accurately diagnosing cystitis is crucial, especially in differentiating it from other conditions presenting with similar symptoms. This article provides a comprehensive guide to the Differential Diagnosis Of Cystitis, ensuring clinicians can effectively distinguish it from related ailments and implement appropriate management strategies. Understanding the nuances of cystitis and its mimics is essential for optimal patient care and to avoid unnecessary treatments.

Etiology of Cystitis

Typically, acute cystitis is a result of bacterial invasion of the bladder. Escherichia coli (E. coli) stands as the predominant culprit, responsible for 75% to 95% of uncomplicated cases in women. This is attributed to the anatomical proximity of the rectum to the urethra and the shorter urethral length in females, facilitating bacterial migration. Other common bacterial pathogens include Klebsiella, Proteus mirabilis, Staphylococcus saprophyticus, and Enterococcus species. Less frequently, other bacteria may be isolated, often representing contamination rather than true infection.

Complicated cystitis, while also frequently caused by E. coli, exhibits a wider spectrum of causative organisms. These can include Enterobacter, Citrobacter, Serratia, Pseudomonas, Enterococci, Staphylococci, and even fungi. Furthermore, complicated UTIs are associated with a higher incidence of antimicrobial resistance, including extended-spectrum beta-lactamase (ESBL) producing bacteria and resistance to carbapenems and fluoroquinolones.

Epidemiology of Cystitis

Urinary tract infections are incredibly common, particularly in women. Statistics indicate that approximately one-third of women will experience a UTI by the age of 24, and about half by age 32. The annual incidence rate in women is around 12%, with sexually active women experiencing a higher rate of 0.5 to 0.7 UTIs per person-year. Risk factors for uncomplicated cystitis in women include sexual activity, spermicide use, new sexual partners, a history of UTIs, and a family history of UTIs in female relatives, as well as being post-menopausal. Cystitis is significantly more prevalent than pyelonephritis, with estimates ranging from 18 to 28 cystitis cases for every pyelonephritis case.

Complicated UTIs show a variable incidence depending on underlying health conditions. For instance, women with diabetes have a higher prevalence of asymptomatic bacteriuria (26%) compared to non-diabetic women (6%). Diabetes also increases the risk of both acute cystitis and pyelonephritis. Renal transplant recipients are also at high risk, with UTI incidence reported between 47% and 75%, especially in the first year post-transplant. Other risk factors for complicated UTIs include kidney stones, immunocompromised states, urinary catheters, urinary tract instrumentation, renal insufficiency, anatomical or functional urinary tract abnormalities, urinary stents, strictures, and obstructive uropathy.

Simple cystitis in men is less common, estimated at fewer than 10 cases per 10,000 men under 65 annually. Symptoms in men mirror those in women, including dysuria, urinary frequency, urgency, and suprapubic pain. However, recurrent symptoms, fever, or pelvic/perineal pain may suggest prostatitis, while systemic symptoms like fever, chills, or flank pain point towards a complicated UTI.

Pathophysiology of Cystitis

Cystitis typically arises from the colonization of the periurethral area by bacteria originating from the fecal or vaginal flora. These pathogens ascend to the urinary bladder, where they can establish infection. Uropathogens often possess virulence factors that enable them to evade host defenses and invade urinary tract tissues. UTIs are less frequent in males due to the longer urethra, drier periurethral environment, and antibacterial properties of prostatic fluid. While traditionally, all UTIs in males were classified as complicated, uncomplicated UTIs can occur, especially in younger, sexually active, or uncircumcised males without complicating risk factors.

Complicated UTIs are largely influenced by host factors. Compromised immune function and voiding dysfunction due to autonomic neuropathy in diabetic patients increase UTI susceptibility. Renal insufficiency can lead to uremic toxin accumulation, weakening host defenses, and reduced renal blood flow can impair antibiotic clearance. Kidney stones can cause obstruction and serve as a nidus for infection. Urinary catheters can facilitate biofilm formation, both internally and externally, and allow pathogens to persist in stagnant urine within the bladder.

E. coli remains the most common bacterial culprit in cystitis cases (75%-95%). Other organisms include Klebsiella pneumoniae and Proteus mirabilis. In patients with recent hospitalizations or prior UTI treatment, pathogens like Pseudomonas, Enterococci, and Staphylococci (S. saprophyticus) may be encountered. Organisms such as lactobacilli, Group B streptococci, and coagulase-negative staphylococci are usually considered contaminants unless present in very high numbers, indicating potential infection.

History and Physical Examination in Cystitis

Patients with acute cystitis commonly present with urinary symptoms such as dysuria (painful urination), urinary frequency, urgency, suprapubic pain or tenderness, and sometimes hematuria (blood in urine). A combination of dysuria and urinary frequency, without vaginal discharge or irritation in women, has a high predictive value (90%) for uncomplicated cystitis. Symptoms can be less typical in very young and elderly patients. Cloudy urine or a “foul odor” alone is generally insufficient for cystitis diagnosis.

Complicated acute cystitis often presents with similar symptoms to uncomplicated cystitis, but specific patient populations may exhibit atypical presentations. For example, individuals with multiple sclerosis might present with neurological deterioration, while those with spinal cord injuries may show autonomic dysfunction or increased spasticity.

Distinguishing cystitis from pyelonephritis relies on the absence of systemic findings like fever, chills, or sepsis in cystitis. Flank pain, costovertebral angle tenderness, nausea, and vomiting suggest upper UTI or pyelonephritis.

Patient history should include prior UTIs, recent antibiotic use, and risk factors for complicated infections, such as diabetes, immunocompromised status, recent urologic procedures, renal transplantation, kidney stones, urinary tract abnormalities, or pregnancy.

Pelvic examinations are important for women, especially with recurrent UTIs, defined as two UTIs within six months or three within a year. Recurrent infections with the same organism may suggest urinary stones, while in men, they might indicate chronic bacterial prostatitis. Urine cultures are essential for diagnosing recurrent or relapsing UTIs.

In frail or debilitated patients, non-specific symptoms like changes in mental or functional status, fevers, chills, and falls may be associated with UTI. However, recent evidence suggests that only urinary changes (color, odor, hematuria) and acute dysuria are reliably linked to documented UTIs. Changes in urine odor and color alone may indicate bacteriuria, but antibiotic treatment might not be warranted without other symptoms like fever. For mental status changes, hydration, observation, and assessment for other causes are recommended.

Evaluation and Diagnostic Modalities for Cystitis

Diagnosis of acute cystitis is usually clinical, based on typical lower UTI symptoms combined with laboratory evidence of pyuria (white blood cells in urine) and/or nitrites. Physical exams may be less critical for cystitis diagnosis but more important for suspected pyelonephritis or vaginitis. In young, non-pregnant women with classic cystitis symptoms and no vaginal discharge, clinical suspicion alone may suffice for diagnosis and treatment initiation without lab confirmation. However, urinalysis and urine culture are highly recommended before antibiotics are started, especially if initial treatment fails.

Urinalysis is the primary lab test. A clean-catch urine sample is usually adequate, but catheterization might be needed for uncontaminated samples, especially in obese women. The risk of UTI from single catheterization in previously uninfected women is low (around 1%).

Visual urine appearance is unreliable for UTI diagnosis. Clear urine can be infected, and cloudy urine can be sterile. Adding acetic acid to cloudy urine can differentiate cloudiness from calcium phosphate debris.

Pyuria, defined as ≥10 WBCs/HPF or leukocytes in unspun urine, is almost always present in cystitis. Absence of pyuria suggests alternative diagnoses.

Urine dipsticks detect leukocyte esterase (from leukocytes) and nitrites (from Enterobacteriaceae). Positive nitrite tests strongly suggest bacteriuria. Acinetobacter, Pseudomonas, and Enterococcus typically don’t convert nitrates to nitrites. Positive dipstick tests for leukocyte esterase or nitrites support cystitis diagnosis in symptomatic patients. However, negative dipstick tests do not rule out UTI reliably.

Treating UTI symptoms based on positive nitrites is reasonable, but consider other diagnoses with negative leukocyte esterase. Having both positive leukocyte esterase and nitrites has a high positive predictive value (85%) and negative predictive value (92%).

Urine culture identifies pathogens and their antibiotic susceptibility. ≥100,000 CFU/mL indicates significant bacteriuria, but ≥1,000 CFU is significant in men and catheterized samples. <100,000 CFU/mL doesn’t exclude UTI. Urine cultures are often unnecessary in uncomplicated cystitis but helpful in persistent symptoms, treatment failures, and considering antibiotic resistance.

Urinalysis and urine cultures are essential before antibiotic therapy in all men with cystitis symptoms and women with complicated UTI risk factors. They are also indicated in atypical symptoms, treatment failure, and symptom recurrence within 2-4 weeks. Pregnancy tests are needed for women of childbearing age.

Men with recurrent cystitis should be evaluated for prostatitis. Urologic evaluation may not be needed for young, sexually active men with a single cystitis episode. Risk factors for complicated UTI warrant urologic evaluation.

Multidrug-resistant organisms pose a growing challenge. Urine cultures are crucial in potentially complicated or difficult infections and in high-risk patients.

Patients with complicated cystitis not responding to antibiotics within 48-72 hours need imaging of the upper urinary tract (CT or ultrasound). CT is usually preferred for detecting obstruction, stones, diverticula, or abscesses. Ultrasound with KUB X-ray can be used to minimize radiation exposure. Cystoscopy may also be considered.

Treatment and Management Strategies for Cystitis

Antibiotic therapy is the mainstay of acute cystitis treatment. Antibiotic selection depends on the patient’s risk of infection with multidrug-resistant organisms. Low-risk patients are treated with first-line agents:

  1. Nitrofurantoin 100 mg twice daily for 5-7 days.
  2. Sulfamethoxazole-trimethoprim (SMX-TMP) double-strength twice daily for 3 days (if local resistance <20%).
  3. Fosfomycin 3 gm as a single oral dose.
  4. Pivmecillinam 400 mg twice daily for 5-7 days (not in the US).

Nitrofurantoin is often the first choice for simple cystitis. It has low resistance, a high cure rate (79%-92%), and is safe in older patients with GFR >60 mL/min. It has poor tissue penetration, making it unsuitable for pyelonephritis or systemic illness. It is less effective against Proteeae group organisms in alkaline urine (pH ≥8). Nitrofurantoin is bacteriostatic and requires at least 5 days of treatment.

Sulfamethoxazole-Trimethoprim (SMX-TMP) is used when local resistance is low (<20%). Trimethoprim alone is an option for sulfa allergies. Resistance to SMX-TMP can develop quickly.

Fosfomycin has a similar cure rate to nitrofurantoin. It is often underutilized in the US due to culture reporting practices. It is active against many resistant organisms, including E. coli and Enterococcus, but should not be routine first-line. It is effective against Gram-positive and Gram-negative bacteria, including vancomycin-resistant strains, but less so against Klebsiella and Pseudomonas. It is not suitable for pyelonephritis due to poor tissue levels. Fosfomycin is bactericidal and can be used in pregnancy (FDA category B). Recent studies suggest potential use in complicated UTIs and pyelonephritis, but more research is needed.

Pivmecillinam is used outside the US (especially in Nordic countries) due to low resistance. It is a urinary-tract-specific penicillin. Like nitrofurantoin, it does not promote resistance but is unsuitable for pyelonephritis or systemic infections due to poor tissue penetration.

Complicated infections typically require 10-14 days of antibiotics. Diabetic patients are at higher risk of yeast infections post-antibiotic treatment.

Antimicrobial selection should be individualized based on patient factors (allergies, side effects, tolerability, local resistance, drug interactions, cost, renal function, compliance, recent antibiotic use). Nitrofurantoin is contraindicated in patients with creatinine clearance or GFR <60 mL/min. SMX-TMP should be avoided if local resistance >20% or with sulfa allergies. Risk factors for resistance include recent healthcare contact, recent SMX-TMP use, and international travel. Nitrofurantoin, fosfomycin, norfloxacin, pivmecillinam, and possibly fosfomycin are not suitable for suspected pyelonephritis due to poor renal tissue penetration.

Alternative or second-line agents for acute cystitis include 5-7 day courses of oral beta-lactams (amoxicillin-clavulanate, cefpodoxime, cefdinir, cefadroxil, cephalexin). If beta-lactams are contraindicated, doxycycline or fluoroquinolones (ciprofloxacin, norfloxacin, levofloxacin) for 3 days (simple UTIs) or 7-14 days (complicated UTIs) can be used. High resistance to SMX-TMP and amoxicillin in many areas limits their use.

Another approach involves initial IV parenteral antibiotics (ceftriaxone, ertapenem, gentamicin/tobramycin) followed by 10-14 days of oral antibiotics based on culture results. Ceftriaxone is preferred, with aminoglycosides reserved for those who cannot receive other options.

Gentamicin bladder instillations can be used for UTIs, especially in neurogenic bladders or self-catheterization, but require catheterization. Chlorhexidine and povidone-iodine instillations are also effective, but not neomycin/bacitracin/polymixin B. Bladder instillation therapy is a reasonable option for patients with recurrent UTIs on self-intermittent catheterization.

Mandelamine can be used prophylactically, especially for recurrent multidrug-resistant infections. It is converted to formaldehyde in acidic urine (pH ≤5.5) and is often given with vitamin C to maintain acidity. Mandelamine should not be used with GFR <10 mL/min.

D-mannose is a non-antibiotic prophylactic agent showing some success, potentially comparable to antibiotic prophylaxis, with few side effects. It is not for treating active UTIs. Dosage is typically 2 grams daily. While promising, data is not conclusive.

Urine culture and sensitivity testing are needed to guide treatment in patients at risk for multidrug-resistant organisms (previous MDR isolate, recent healthcare stay, travel to high-prevalence areas, recent broad-spectrum antibiotic use). Empiric regimens can include nitrofurantoin, SMX-TMP, fosfomycin, and pivmecillinam (if available). Deferring treatment until culture results are available is another option, especially if first-line agents are contraindicated.

Symptomatic treatment with analgesics like phenazopyridine can be used for severe dysuria but is not therapeutic and does not affect infection course.

Cystitis in men is uncommon and less studied. In healthy men without complicated UTI risk factors or symptoms suggesting infection outside the bladder, treatment is similar to complicated UTIs in women. For men with severe symptoms, anatomical abnormalities, or suspected prostate involvement, fluoroquinolones are recommended as empiric therapy pending culture results and quinolone resistance patterns due to broad spectrum and tissue penetration. Doxycycline, SMX-TMP, and cephalosporins can also be used initially to minimize quinolone resistance. All UTIs in men are generally considered complicated due to risk of chronic prostatitis, which may develop later. Prostate-penetrating antibiotics (doxycycline, SMX-TMP, quinolones) are recommended for 4-6 weeks to ensure prostate penetration and reduce chronic prostatitis risk.

Patients not responding to antibiotics within 48-72 hours or with symptom recurrence need further evaluation for other causes or resistant organisms. Urine culture and susceptibility testing should be performed, and empiric antibiotics changed, adjusting based on susceptibility results.

Differential Diagnosis of Cystitis

Accurate differential diagnosis of cystitis is essential because several conditions can mimic its symptoms. In women presenting with dysuria, common differential diagnoses include:

  • Vaginitis: Typically presents with vaginal discharge, dyspareunia (painful intercourse), and pruritus (itching). Causes include bacterial vaginosis, trichomoniasis, or yeast infections. Urinary symptoms are less prominent.
  • Urethritis: Inflammation of the urethra, often sexually transmitted. Urinalysis shows pyuria but no bacteriuria. Sexually active women are at higher risk.

Other conditions to consider in the differential diagnosis of cystitis include:

  • Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC): Mimics cystitis symptoms (frequency, urgency, dysuria) but lacks evidence of infection (no pyuria, bacteriuria, or positive urine cultures). PBS/IC is a diagnosis of exclusion, considered after ruling out infections and other causes.
  • Pelvic Inflammatory Disease (PID): Characterized by pelvic and lower abdominal pain, fever, and possible cervical discharge. UTI symptoms are less central to the presentation compared to cystitis.
  • Prostatitis: In men, prostatitis should be considered in the differential diagnosis of cystitis, especially with fever, malaise, perineal pain, or obstructive urinary symptoms. Recurrent UTIs in men are a strong indicator of chronic bacterial prostatitis. Ejaculatory pain or vague pelvic discomfort, along with a tender, boggy prostate on rectal exam, are suggestive. Urinalysis may be negative in some forms of prostatitis.
  • Atrophic Vaginitis: Occurs in post-menopausal women due to estrogen deficiency. Presents with vaginal dryness, dyspareunia, thin, watery vaginal discharge, and pale labia and vaginal lining. Dysuria can be present, but urinary urgency and frequency are less typical compared to cystitis.

A table summarizing the key differentiating features can be helpful in the differential diagnosis of cystitis:

Condition Key Symptoms Urinary Symptoms (Dysuria, Frequency, Urgency) Vaginal Discharge/Irritation Fever/Systemic Symptoms Pyuria Bacteriuria
Cystitis Suprapubic pain, hematuria (sometimes) Prominent Absent Absent Yes Yes
Vaginitis Vaginal itching, odor, dyspareunia Less prominent Present Absent No No
Urethritis May be present Absent Absent Yes No
PBS/IC Chronic pelvic pain Prominent Absent Absent No No
PID Pelvic/abdominal pain, cervical discharge Less prominent May be present Present No No
Prostatitis Perineal pain, ejaculatory pain (men) May be present Absent May be present Yes/No Yes/No
Atrophic Vaginitis Vaginal dryness, dyspareunia May be present, less typical Thin, watery discharge Absent No No

This table provides a simplified overview and should be used in conjunction with a thorough patient history, physical examination, and appropriate laboratory tests to arrive at an accurate diagnosis and effective management plan.

Prognosis of Cystitis

Uncomplicated cystitis generally has a favorable prognosis. Symptoms typically improve within three days of starting antibiotic treatment. However, recurrence is common, with approximately 25% of women experiencing recurrent cystitis within six months of their first UTI. This risk increases with each subsequent UTI. Complications from uncomplicated cystitis are rare, especially with appropriate treatment. Bacteremia and sepsis are uncommon in uncomplicated cases.

Emphysematous cystitis, a rare but serious complication, involves gas formation in the bladder wall and can be life-threatening if not managed promptly. It is more likely to cause abdominal pain (80%) compared to simple cystitis (50%). Pneumaturia (gas in urine) is present in about 70% of cases, and bacteremia in about half. Diagnosis is best confirmed by CT scan. Diabetes is the primary risk factor, present in about two-thirds of cases, along with female gender, immunocompromised conditions, urinary abnormalities, obstruction, catheters, age over 60, and chronic UTIs.

Treatment for emphysematous cystitis is primarily medical with antibiotics, but catheter drainage is needed for retention, incomplete bladder emptying, or significant hematuria. Necrotizing infection of the bladder wall occurs in about 10% of patients, requiring surgical resection.

Complications of Cystitis

While usually uncomplicated, cystitis can lead to more serious conditions if not appropriately managed or in certain patient populations. Potential complications include:

  • Pyelonephritis (kidney infection)
  • Renal or perinephric abscess formation
  • Renal vein thrombosis
  • Sepsis (blood infection)
  • Acute renal failure
  • Emphysematous pyelonephritis
  • Prostatitis (in men)

Deterrence and Patient Education for Cystitis

Patient education is crucial in preventing cystitis and managing recurrent episodes. Key points for patient education include:

  • Antibiotic Adherence: Emphasize the importance of completing the prescribed antibiotic course as directed, even if symptoms improve.
  • Fluid Intake: Encourage increased oral fluid intake to promote urinary flushing and dilute urine, which can help prevent bacterial growth.
  • Post-Intercourse Voiding: For sexually active patients, advise voiding after intercourse to help expel bacteria that may have entered the urethra.
  • Hygiene Practices: Proper hygiene, including wiping front to back, can help reduce bacterial contamination of the urethra.
  • Follow-up: Advise patients to seek follow-up if symptoms worsen or do not improve after starting antibiotics.

Pearls and Other Considerations in Cystitis Management

  • Bladder Instillation Therapy: Consider bladder instillation therapy, particularly with gentamicin, for patients on dialysis or those performing regular intermittent self-catheterization with recurrent UTIs.
  • Prophylactic Agents: Mandelamine with vitamin C or D-mannose can be considered for UTI prevention in select patients with recurrent infections, although further research is needed to definitively confirm their effectiveness.
  • New Antibiotics: Gepotidacin, a novel antibiotic in a new chemical class, shows promise for treating UTIs, including those resistant to current antibiotics. It is currently investigational but may become a valuable option if approved.
  • Vaccine Development: Research into vaccines for UTI prevention is ongoing, with some initial attempts showing marginal success. Approaches include whole bacterial cell vaccines and those based on E. coli components.
  • Improved Hygiene: Emphasize optimal personal hygiene practices to reduce the risk of recurrent UTIs. Specific suggestions include handwashing before wiping, using wipes instead of toilet paper, front-to-back wiping, showers instead of baths, gentle, non-irritating soaps, soft washcloths, and washing the vaginal opening first.

Enhancing Healthcare Team Outcomes in Cystitis Management

Effective management of cystitis, especially complicated and recurrent cases, requires an interprofessional healthcare team approach. Key elements for improved outcomes include:

  • Patient Education: All clinicians should emphasize increased fluid intake and medication compliance. Pharmacists can play a key role in medication education and reconciliation. Nurses can educate sexually active women about post-coital voiding.
  • Referral: Patients with recurrent infections should be referred to a urologist for comprehensive evaluation.
  • Communication: Open communication among team members is essential for optimal patient care. Any team member noticing issues or changes in patient status should document findings and communicate with the appropriate team members.

Outcomes:

Uncomplicated cystitis typically resolves well with appropriate antibiotic therapy. However, recurrent infections are common, particularly in women. Men with first-time cystitis episodes should be referred to a urologist to rule out underlying structural or functional abnormalities. Immunocompromised patients and those with diabetes are at higher risk of complications like sepsis and require close monitoring, potentially involving infectious disease specialists.

Review Questions (Example – Not for Inclusion in Article)

  1. What are the most common causative agents of uncomplicated cystitis?
  2. List three key features in the differential diagnosis of cystitis to distinguish it from vaginitis.
  3. Which antibiotic is often considered first-line for uncomplicated cystitis and why?
  4. What are the risk factors for complicated cystitis?
  5. Describe the role of urine culture in the management of cystitis.

References

  1. Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13507. [PubMed: 30793386]
  2. Duane S, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, Moore M, Little P, Devane D. COSUTI: a protocol for the development of a core outcome set (COS) for interventions for the treatment of uncomplicated urinary tract infection (UTI) in adults. Trials. 2019 Feb 07;20(1):106. [PMC free article: PMC6367821] [PubMed: 30732617]
  3. Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian Omran D. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Bucur). 2010 Apr;5(2):111-5. [PMC free article: PMC3150015] [PubMed: 21977133]
  4. Byron JK. Urinary Tract Infection. Vet Clin North Am Small Anim Pract. 2019 Mar;49(2):211-221. [PubMed: 30591189]
  5. Karamali M, Shafabakhsh R, Ghanbari Z, Eftekhar T, Asemi Z. Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression. J Cell Physiol. 2019 Aug;234(8):12301-12308. [PubMed: 30609029]
  6. Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ. Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infect Dis. 2018 Nov;5(11):ofy297. [PMC free article: PMC6284462] [PubMed: 30539040]
  7. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ., EMERGEncy ID Net Study Group. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1). Emerg Infect Dis. 2016 Sep;22(9):1594-603. [PMC free article: PMC4994338] [PubMed: 27532362]
  8. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR., VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013 Nov;57(9):1256-65. [PMC free article: PMC3792724] [PubMed: 23926176]
  9. Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;100(3):271-278. [PubMed: 29539622]
  10. Suárez Fernández ML, Ridao Cano N, Álvarez Santamarta L, Gago Fraile M, Blake O, Díaz Corte C. A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients. Diagnostics (Basel). 2021 Aug 12;11(8) [PMC free article: PMC8392421] [PubMed: 34441390]
  11. Sabih A, Leslie SW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Complicated Urinary Tract Infections. [PubMed: 28613784]
  12. Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol. 1993 May;149(5):1046-8. [PubMed: 8483206]
  13. Tyagi P, Moon CH, Janicki J, Kaufman J, Chancellor M, Yoshimura N, Chermansky C. Recent advances in imaging and understanding interstitial cystitis. F1000Res. 2018;7 [PMC free article: PMC6234747] [PubMed: 30473772]
  14. Pinto H, Simões M, Borges A. Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2021 Jul 08;10(7) [PMC free article: PMC8300799] [PubMed: 34356749]
  15. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013 Nov 14;369(20):1883-91. [PMC free article: PMC4041367] [PubMed: 24224622]
  16. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002 May 22-29;287(20):2701-10. [PubMed: 12020306]
  17. Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc. 2009 Jun;57(6):963-70. [PMC free article: PMC2692075] [PubMed: 19490243]
  18. Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. 2019 Aug;202(2):282-289. [PubMed: 31042112]
  19. Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. J Am Med Dir Assoc. 2014 Feb;15(2):133-9. [PubMed: 24461240]
  20. Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract. 2011 May 19;12:36. [PMC free article: PMC3142216] [PubMed: 21592413]
  21. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV. Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. BMJ. 2019 Feb 27;364:l440. [PMC free article: PMC6391655] [PubMed: 30814052]
  22. Kulchavenya EV, Neymark AI, Borisenko DV, Kapsargin FP. [Acute uncomplicated cysititis: do we follow the guidelines?]. Urologiia. 2018 Dec;(6):66-69. [PubMed: 30742380]
  23. Phamnguyen TJ, Murphy G, Hashem F. Single centre observational study on antibiotic prescribing adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infection. Infect Dis Health. 2019 May;24(2):75-81. [PubMed: 30598405]
  24. Bono MJ, Leslie SW, Reygaert WC, Doerr C. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections (Nursing) [PubMed: 33760460]
  25. Bono MJ, Leslie SW, Reygaert WC. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 13, 2023. Uncomplicated Urinary Tract Infections. [PubMed: 29261874]
  26. Swamy S, Kupelian AS, Khasriya R, Dharmasena D, Toteva H, Dehpour T, Collins L, Rohn JL, Malone-Lee J. Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis. Int Urogynecol J. 2019 Mar;30(3):409-414. [PMC free article: PMC6394536] [PubMed: 30564872]
  27. May M, Schostak M, Lebentrau S., MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. Int Urogynecol J. 2019 Feb;30(2):335-336. [PubMed: 30564871]
  28. Bellazreg F, Abid M, Lasfar NB, Hattab Z, Hachfi W, Letaief A. Diagnostic value of dipstick test in adult symptomatic urinary tract infections: results of a cross-sectional Tunisian study. Pan Afr Med J. 2019;33:131. [PMC free article: PMC6754830] [PubMed: 31558930]
  29. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004 Apr 15;38(8):1150-8. [PubMed: 15095222]
  30. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians. Akl EA, Bledsoe TA, Forciea MA, Haeme R, Kansagara DL, Marcucci M, Miller MC, Obley AJ. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-827. [PubMed: 33819054]
  31. McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc. 2011 Jun;86(6):480-8. [PMC free article: PMC3104907] [PubMed: 21576512]
  32. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64. [PubMed: 26066581]
  33. Sheele JM, Libertin CR, Fink I, Jensen T, Dasalla N, Lyon TD. Alkaline Urine in the Emergency Department Predicts Nitrofurantoin Resistance. J Emerg Med. 2022 Mar;62(3):368-377. [PubMed: 35000812]
  34. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999 Mar;43 Suppl A:67-75. [PubMed: 10225575]
  35. Kavatha D, Giamarellou H, Alexiou Z, Vlachogiannis N, Pentea S, Gozadinos T, Poulakou G, Hatzipapas A, Koratzanis G. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother. 2003 Mar;47(3):897-900. [PMC free article: PMC149311] [PubMed: 12604518]
  36. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999 Oct;29(4):745-58. [PubMed: 10589881]
  37. Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis. 1988 Jun;157(6):1239-42. [PubMed: 3259613]
  38. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999 Nov;21(11):1864-72. [PubMed: 10890258]
  39. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016 Apr;29(2):321-47. [PMC free article: PMC4786888] [PubMed: 26960938]
  40. Schulz GS, Schütz F, Spielmann FVJ, da Ros LU, de Almeida JS, Ramos JGL. Single-dose antibiotic therapy for urinary infections during pregnancy: A systematic review and meta-analysis of randomized clinical trials. Int J Gynaecol Obstet. 2022 Oct;159(1):56-64. [PubMed: 34995367]
  41. Hatlen TJ, Flor R, Nguyen MH, Lee GH, Miller LG. Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020 Jul 01;75(7):1993-1997. [PubMed: 32303061]
  42. Wald-Dickler N, Lee TC, Tangpraphaphorn S, Butler-Wu SM, Wang N, Degener T, Kan C, Phillips MC, Cho E, Canamar C, Holtom P, Spellberg B. Fosfomycin vs Ertapenem for Outpatient Treatment of Complicated Urinary Tract Infections: A Multicenter, Retrospective Cohort Study. Open Forum Infect Dis. 2022 Jan;9(1):ofab620. [PMC free article: PMC8754378] [PubMed: 35036466]
  43. Graninger W. Pivmecillinam–therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. [PubMed: 14527775]
  44. Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N, Bru JP, Mckinnon C, O’Doherty B, Spiegel W, Van Balen FA, Menday P. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis. 2002;34(7):487-92. [PubMed: 12195873]
  45. Nace DA, Perera SK, Hanlon JT, Saracco S, Anderson G, Schweon SJ, Klein-Fedyshin M, Wessel CB, Mulligan M, Drinka PJ, Crnich CJ. The Improving Outcomes of UTI Management in Long-Term Care Project (IOU) Consensus Guidelines for the Diagnosis of Uncomplicated Cystitis in Nursing Home Residents. J Am Med Dir Assoc. 2018 Sep;19(9):765-769.e3. [PMC free article: PMC8043108] [PubMed: 30037743]
  46. Cox L, He C, Bevins J, Clemens JQ, Stoffel JT, Cameron AP. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can Urol Assoc J. 2017 Sep;11(9):E350-E354. [PMC free article: PMC5798439] [PubMed: 29382457]
  47. Lala V, Leslie SW, Minter DA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 10, 2023. Acute Cystitis. [PubMed: 29083726]
  48. Ziadeh T, Chebel R, Labaki C, Saliba G, Helou EE. Bladder instillation for urinary tract infection prevention in neurogenic bladder patients practicing clean intermittent catheterization: A systematic review. Urologia. 2022 May;89(2):261-267. [PubMed: 34612750]
  49. Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti Infect Ther. 2014 May;12(5):549-54. [PubMed: 24689705]
  50. Kevorkian CG, Merritt JL, Ilstrup DM. Methenamine mandelate with acidification: an effective urinary antiseptic in patients with neurogenic bladder. Mayo Clin Proc. 1984 Aug;59(8):523-9. [PubMed: 6379319]
  51. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. [PubMed: 23633128]
  52. Kyriakides R, Jones P, Somani BK. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus. 2021 Sep;7(5):1166-1169. [PubMed: 32972899]
  53. Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020 Aug;223(2):265.e1-265.e13. [PMC free article: PMC7395894] [PubMed: 32497610]
  54. De Nunzio C, Bartoletti R, Tubaro A, Simonato A, Ficarra V. Role of D-Mannose in the Prevention of Recurrent Uncomplicated Cystitis: State of the Art and Future Perspectives. Antibiotics (Basel). 2021 Apr 01;10(4) [PMC free article: PMC8066587] [PubMed: 33915821]
  55. Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007 Jan;86(1):47-53. [PubMed: 17220755]
  56. Thomas AA, Lane BR, Thomas AZ, Remer EM, Campbell SC, Shoskes DA. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007 Jul;100(1):17-20. [PubMed: 17506870]
  57. Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, Xu S, Dumont E, Janmohamed S. Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Infect Dis Ther. 2022 Dec;11(6):2297-2310. [PMC free article: PMC9589544] [PubMed: 36271314]
  58. Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322. [PMC free article: PMC9664842] [PubMed: 36255258]
  59. Tiffany C, Dumont EF, Hossain M, Srinivasan M, Swift B. Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects. Clin Transl Sci. 2022 Sep;15(9):2251-2264. [PMC free article: PMC9468557] [PubMed: 35769034]
  60. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother. 2016 Jan 04;60(3):1918-23. [PMC free article: PMC4776004] [PubMed: 26729499]
  61. Uehling DT, Hopkins WJ, Balish E, Xing Y, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial. J Urol. 1997 Jun;157(6):2049-52. [PubMed: 9146577]
  62. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003 Sep;170(3):867-9. [PubMed: 12913718]
  63. Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007 Apr;177(4):1349-53; quiz 1591. [PubMed: 17382730]
  64. Eldridge GR, Hughey H, Rosenberger L, Martin SM, Shapiro AM, D’Antonio E, Krejci KG, Shore N, Peterson J, Lukes AS, Starks CM. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study. Hum Vaccin Immunother. 2021 May 04;17(5):1262-1270. [PMC free article: PMC8078672] [PubMed: 33325785]
  65. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 1997 Apr 25;276(5312):607-11. [PubMed: 9110982]
  66. Forsyth VS, Himpsl SD, Smith SN, Sarkissian CA, Mike LA, Stocki JA, Sintsova A, Alteri CJ, Mobley HLT. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection. mBio. 2020 Apr 28;11(2) [PMC free article: PMC7188996] [PubMed: 32345645]
  67. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013 Dec;190(6):1981-9. [PubMed: 23867306]
  68. Wang Q, Sun M, Ma C, Lv H, Lu P, Wang Q, Liu G, Hu Z, Gao Y. Emphysematous pyelonephritis and cystitis in a patient with uremia and anuria: A case report and literature review. Medicine (Baltimore). 2018 Nov;97(45):e11272. [PMC free article: PMC6250534] [PubMed: 30407278]

Disclosures

Disclosure: Raymund Li declares no relevant financial relationships with ineligible companies.

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *